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Tolerance is a physiological mechanism that prevents attacks on our own cells and tissues whilst 
allowing immune responses directed against tumours and invading pathogens. Autoimmunity is an aggressive 
attack by the immune system on tissues and tissue functions that results from a loss of tolerance which can 
cause chronic and debilitating symptoms. Hence, reinstating tolerance to achieve physiological homeostasis is 
highly warranted. 
 In recent years significant progress has been made in our understanding of tolerance and how 
auto-aggression is actively controlled by multiple layers of immune regulatory mechanisms. This thesis 
describes a unique tolerance-inducing platform that may find clinical use in the treatment of several 
autoimmune diseases. The CTA1R7K-X-DD platform is a fusion protein that consists of three elements with 
their own respective properties; a targeting unit (DD), a disease-specific peptide (X), and an inactivated mutant 
of the immunomodulatory cholera toxin A1-subunit (CTA1R7K). I have exploited this platform using different 
peptide inserts (X) to investigate its mechanism of action and function in two experimental models of human 
autoimmune diseases, namely rheumatoid arthritis (RA) and multiple sclerosis (MS).  
The tolerogenic CTA1R7K-COL-DD fusion protein is a therapeutically effective means to prevent 
collagen-induced arthritis (CIA) in mice and my aim was to understand the mechanisms by which the fusion 
protein reinstates tolerance. My research will contribute to a better understanding of immune regulation 
during autoimmunity, and provide a strategy to interfere with the progression of autoimmune diseases. By 
comparing the tolerogenic fusion protein with its immunoenhancing, enzymatically active, counterpart  
(CTA1-X-DD), I identified a yin-and-yang effect of the two fusion proteins on migratory dendritic cells (DCs), 
which were found to be the primary target cells in vivo after intranasal immunizations. While the enzymatically 
active CTA1-X-DD fusion protein induced the expression of co-stimulatory molecules on the DC, inactive 
CTA1R7K-X-DD instead promoted a set of genes associated with Tr1 induction and co-inhibition. Most 
importantly, the IL-27 cytokine was upregulated in both DCs and T cells, a signalling pathway known to be 
important in Tr1 induction and the regulation of effector responses. The differential effects observed on the DC 
populations were dependent on enzymatic activity and translated into differences in downstream T cell 
responses. I studied these two populations in detail to dissect the immunomodulating events that participated 
in the development of tolerance or immunity.  
In the second half of my thesis work I have investigated the therapeutic effect of the fusion 
protein carrying disease-relevant peptides in the experimental autoimmune encephalitis (EAE) model. I used 
this model to further demonstrate the effects of our fusion protein on disease development, focusing on 
regulatory CD4 T cell subsets and the functional importance of the IL-27 pathway in tolerance induction. Finally, 
to meet the need for simple treatments in the clinic I have evaluated whether there would be a formulation 
that is cost-effective to produce, which may also secure good patient compliance. To this end, I have 
collaborated with a group that expressed the fusion protein in an edible plant. This allowed me to test whether 
oral administration of the fusion protein, when bioencapsulated, could be used to treat CIA. I found that 
treated mice overall exhibited significantly reduced symptoms and in fact, some mice showed no symptoms at 
all. Thus, this proof-of-principle study showed that a protein-based pharmaceutical administered in the form of 
a transgenic plant might be clinically feasible for tolerance induction.  
My thesis identifies several molecular features in the early tolerization process in targeted DCs 
and the subsequent generation of CD4 T cells that help explain the tolerogenic functions of the CTA1R7K-X-DD 
fusion protein. My research also provides experimental evidence which indicate that the CTA1R7K-X-DD fusion 
protein could be a potential therapeutic agent for treatment of RA, MS and possibly other autoimmune 
diseases.  
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